OBJECTIVE: By employing the Cancer Rehabilitation and Evaluation System short form (CARES-SF) prospectively we wanted to focus on the rehabilitation needs after high-dose chemotherapy (HDC) and stem cell transplantation, in order to identify problems that should be addressed by health-care professionals during the course of disease and treatment. METHODS: The CARES-SF was administered before and at 2, 6 and 12 months post-transplant to 130 cancer patients treated with HDC and allogeneic (SCT) or autologous stem cell transplantation (ASCT). Physical function scale scores were compared with the corresponding scale of the EORTC QLQ-C30. RESULTS: The SCT group reported significantly better physical function than the ASCT group before transplant on both the CARES-SF (p<0.0001) and the EORTC QLQ-C30 (p<0.01). Almost identical mean CARES-SF scores across groups (SCT: 0.7-1.4, ASCT: 0.8-1.3) were found at the subsequent assessments, consistent with the QLQ-C30 data. Correlations between CARES-SF and QLQ-C30 Physical Function Scales ranged from 0.45 to 0.65. The SCT group had better psychosocial subscale scores (mean 0.4 and 0.5 versus ASCT: 0.7 and 0.8, p < 0.01) at the 6 and 12-month assessments, as well as better satisfaction on the marital subscale ( p=0.01) 6 months post-transplant. Few patients requested specific help: 19% at baseline with 'fear of the cancer progressing' and 9% with 'reduction in physical energy' after 6 and 12 months. CONCLUSION: The CARES-SF detected differences across groups of patients as well as within-patient changes over time. The possibility for patients to express their need for professional assistance renders the CARES-SF appropriate after SCT/ASCT. The sexual, marital and medical interaction subscales in particular address specific issues of relevance for follow-up care, compared with more traditional questionnaires assessing health related quality of life (HRQOL). Copyright 2003 John Wiley & Sons, Ltd.
OBJECTIVE: By employing the Cancer Rehabilitation and Evaluation System short form (CARES-SF) prospectively we wanted to focus on the rehabilitation needs after high-dose chemotherapy (HDC) and stem cell transplantation, in order to identify problems that should be addressed by health-care professionals during the course of disease and treatment. METHODS: The CARES-SF was administered before and at 2, 6 and 12 months post-transplant to 130 cancerpatients treated with HDC and allogeneic (SCT) or autologous stem cell transplantation (ASCT). Physical function scale scores were compared with the corresponding scale of the EORTC QLQ-C30. RESULTS: The SCT group reported significantly better physical function than the ASCT group before transplant on both the CARES-SF (p<0.0001) and the EORTC QLQ-C30 (p<0.01). Almost identical mean CARES-SF scores across groups (SCT: 0.7-1.4, ASCT: 0.8-1.3) were found at the subsequent assessments, consistent with the QLQ-C30 data. Correlations between CARES-SF and QLQ-C30 Physical Function Scales ranged from 0.45 to 0.65. The SCT group had better psychosocial subscale scores (mean 0.4 and 0.5 versus ASCT: 0.7 and 0.8, p < 0.01) at the 6 and 12-month assessments, as well as better satisfaction on the marital subscale ( p=0.01) 6 months post-transplant. Few patients requested specific help: 19% at baseline with 'fear of the cancer progressing' and 9% with 'reduction in physical energy' after 6 and 12 months. CONCLUSION: The CARES-SF detected differences across groups of patients as well as within-patient changes over time. The possibility for patients to express their need for professional assistance renders the CARES-SF appropriate after SCT/ASCT. The sexual, marital and medical interaction subscales in particular address specific issues of relevance for follow-up care, compared with more traditional questionnaires assessing health related quality of life (HRQOL). Copyright 2003 John Wiley & Sons, Ltd.
Authors: Devesh Oberoi; Victoria White; John Seymour; H Miles Prince; Simon Harrison; Michael Jefford; Ingrid Winship; David Hill; Damien Bolton; Anne Kay; Jeremy Millar; Nicole Wong Doo; Graham Giles Journal: J Cancer Surviv Date: 2017-01-31 Impact factor: 4.442
Authors: Catherine E Mosher; William H Redd; Christine M Rini; Jack E Burkhalter; Katherine N DuHamel Journal: Psychooncology Date: 2009-02 Impact factor: 3.894
Authors: Rachel Phelan; Annie Im; Rebecca L Hunter; Yoshihiro Inamoto; Maria Teresa Lupo-Stanghellini; Alicia Rovo; Sherif M Badawy; Linda Burns; Hesham Eissa; Hemant S Murthy; Pinki Prasad; Akshay Sharma; Elizabeth Suelzer; Vaibhav Agrawal; Mahmoud Aljurf; Karen Baker; Grzegorz W Basak; David Buchbinder; Zachariah DeFilipp; Lana Desnica Grkovic; Ajoy Dias; Hermann Einsele; Michael L Eisenberg; Narendranath Epperla; Nosha Farhadfar; Arthur Flatau; Robert Peter Gale; Hildegard Greinix; Betty K Hamilton; Shahrukh Hashmi; Peiman Hematti; Kareem Jamani; Dipnarine Maharaj; John Murray; Seema Naik; Sunita Nathan; Steven Pavletic; Zinaida Peric; Drazen Pulanic; Richard Ross; Andrea Salonia; Isabel Sanchez-Ortega; Bipin N Savani; Tal Schechter; Ami J Shah; Stephanie M Smith; John A Snowden; Amir Steinberg; Douglas Tremblay; Sarah C Vij; Lauren Walker; Daniel Wolff; Jean A Yared; Hélène Schoemans; André Tichelli Journal: Transplant Cell Ther Date: 2021-10-29
Authors: Rachel Phelan; Annie Im; Hélène Schoemans; André Tichelli; Rebecca L Hunter; Yoshihiro Inamoto; Maria Teresa Lupo-Stanghellini; Alicia Rovo; Sherif M Badawy; Linda Burns; Hesham Eissa; Hemant S Murthy; Pinki Prasad; Akshay Sharma; Elizabeth Suelzer; Vaibhav Agrawal; Mahmoud Aljurf; Karen Baker; Grzegorz W Basak; David Buchbinder; Zachariah DeFilipp; Lana Desnica Grkovic; Ajoy Dias; Hermann Einsele; Michael L Eisenberg; Narendranath Epperla; Nosha Farhadfar; Arthur Flatau; Robert Peter Gale; Hildegard Greinix; Betty K Hamilton; Shahrukh Hashmi; Peiman Hematti; Kareem Jamani; Dipnarine Maharaj; John Murray; Seema Naik; Sunita Nathan; Steven Pavletic; Zinaida Peric; Drazen Pulanic; Richard Ross; Andrea Salonia; Isabel Sanchez-Ortega; Bipin N Savani; Tal Schechter; Ami J Shah; Stephanie M Smith; John A Snowden; Amir Steinberg; Douglas Tremblay; Sarah C Vij; Lauren Walker; Daniel Wolff; Jean A Yared Journal: Bone Marrow Transplant Date: 2022-05-06 Impact factor: 5.174